PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Neurosci. Author manuscript; available in PMC Sep 16, 2011.
Published in final edited form as:
PMCID: PMC3073846
NIHMSID: NIHMS279954
Autoantibodies in Melanoma-Associated Retinopathy Target TRPM1 Cation Channels of Retinal ON Bipolar Cells
Anuradha Dhingra,1 Marie E. Fina,1 Adam Neinstein,1 David J. Ramsey,2 Ying Xu,3 Gerald A. Fishman,4 Kenneth R. Alexander,4 Haohua Qian,4* Neal S. Peachey,5,6,7 Ronald G. Gregg,8,9 and Noga Vardi1
1Neurosci., Univ. Pennsylvania Sch. Med., Philadelphia, PA
2The Wilmer Eye Inst., John Hopkins, Baltimore, MD
3Joint Lab for Brain Function and Health, Jinan Univ. and the Univ. of Hong Kong, Jinan Univ., Guangzhou, China
4Ophthalmology and Visual Sci., Univ. of Illinois at Chicago, Chicago, IL
5Cleveland Veterans Affairs Medical Center, Cleveland, Ohio 44196
6Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195
7Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio 44106
8Department of Biochemistry and Molecular Biology University of Louisville, Louisville, Kentucky 40202
9Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, Kentucky 40202
*Current address: National Eye Institute, Bethesda, MD 20892.
Correspondence: Dr. Anuradha Dhingra 123 Anatomy/Chemistry Building, Philadelphia, PA 19104-6058 ; dhingra/at/mail.med.upenn.edu
Melanoma-associated retinopathy (MAR) is characterized by night blindness, photopsias, and a selective reduction of the electroretinogram b-wave. In certain cases, the serum contains autoantibodies that react with ON bipolar cells, but the target of these autoantibodies has not been identified. Here we show that the primary target of autoantibodies produced in MAR patients with reduced b-wave is the TRPM1 cation channel, the newly identified transduction channel in ON bipolar cells. Sera from two well characterized MAR patients, but not from a control subject, stained human embryonic kidney cells transfected with the TRPM1 gene, and Western blots probed with these MAR sera showed the expected band size (~180 kDa). Staining of mouse and primate retina with MAR sera revealed immunoreactivity in all types of ON bipolar cells. Similar to staining for TRPM1, staining with the MAR sera was strong in dendritic tips and somas and was weak or absent in axon terminals. This staining co-localized with GFP in Grm6-GFP transgenic mice, where GFP is expressed in all and only ON bipolar cells, and also co-localized with Gαo, a marker for all types of ON bipolar cells. The staining in ON bipolar cells was confirmed to be specific to TRPM1 because MAR serum did not stain these cells in a Trpm1−/− mouse. Evidence suggests that the recognized epitope is likely intracellular, and the sera can be internalized by retinal cells. We conclude that the vision of at least some patients with MAR is compromised due to autoantibody-mediated inactivation of the TRPM1 channel.
Keywords: retina, autoimmune disorder, ON bipolar cells, cancer
Melanoma-associated retinopathy (MAR) is an infrequently encountered condition seen in some cutaneous melanoma patients, who experience a rapid onset of night blindness, and other visual abnormalities (Berson and Lessell, 1988; Alexander et al., 1992; Milam et al., 1993; Keltner et al., 2001; Heckenlively and Ferreyra, 2008). The dark-adapted electroretinogram (ERG) of these patients typically has a normal a-wave but a greatly reduced b-wave, consistent with a defect in neurotransmission from photoreceptors to ON bipolar cells, which generate the b-wave component. The symptoms of night blindness and the selective ERG b-wave reduction resemble the complete form of congenital stationary night blindness (cCSNB), which is caused by mutations in genes that mediate the transduction cascade in ON bipolar cells (reviewed by McCall and Gregg, 2008; Morgans et al., 2010).
Based on the observation that the serum of MAR patients reacts with rod bipolar cells (Milam et al., 1993), it was originally proposed that MAR results from autoantibodies that circulate in the patient's serum. In support of this proposal, injection of purified IgG from MAR patients into monkey eyes reduces the amplitude of the ERG b-wave (Lei et al., 2000), and suppression of the immune response may induce partial visual recovery (Keltner et al., 2001). Efforts to identify the antigens that are targeted by the autoantibodies have revealed a number of photoreceptor proteins, but none specific to ON bipolar cells (Potter et al., 2002; Hartmann et al., 2005; Lu et al., 2009).
TRPM1 (also known as melastatin 1, or MLSN1) was recently identified as the cation channel that mediates the light response in ON bipolar cells (Morgans et al., 2009; Shen et al., 2009; Koike et al., 2010). Mutations in TRPM1 have been linked to human cCSNB (Audo et al., 2009; Li et al., 2009; van Genderen et al., 2009). Moreover, Trpm1 knockout mice display ERG b-wave reductions as does the Appaloosa horse model of cCSNB in which the night blindness and coat-spotting traits have been linked to the TRPM1 locus (Bellone et al., 2008, 2010). These observations, the expression of TRPM1 in melanocytes, and its downregulation in melanoma cells (Duncan et al., 2001; Hammock et al., 2006) suggest that MAR may involve the generation of TRPM1 antibodies. In the present report, we present evidence in support of this hypothesis.
Antibodies, sera, and plasmids
Sera were obtained following informed consent from three well-characterized male MAR patients (MAR1-3), and one visually normal male subject. MAR1 is the patient described in Alexander et al. (1992) and is also Patient 2 of Milam et al. (1993); MAR2 is Patient 2 of Alexander et al. (2002, 2004); and MAR 3 is Patient 1 of Alexander et al. (2002, 2004).
The primary antibodies used included: anti-TRPM1 raised against the C-terminus of human TRPM1 (Sigma; cat no. HPA014785), mouse anti-Gαo (Millipore; cat no. MAB3073), anti c-myc (9E10) (Developmental Studies Hybridoma Bank) and anti-GABAA raised against the ß2/3 subunit of the GABAA receptor (Chemicon Int.; clone BD17). The plasmid encoding human TRPM1 fused to myc tag was a gift from Dr. Denise Montell (Johns Hopkins School of Medicine, MD) and plasmid encoding neuropilin1 fused to a myc tag was a gift from Dr. Jonathan Raper (University of Pennsylvania, PA).
Sample preparation and immunocytochemistry
Fixed or frozen monkey retinas (Macaca fascicularis) (from males and females) were obtained from Covance Research Products Inc. (Alice, TX) following unrelated experiments. Male and female mouse tissue was from the wild-type C57BL/6 strain, transgenic Grm6-GFP mice (Dhingra et al., 2008), or Trpm1 knockout mice (as described by Shen et al., 2009) (two males one female). Retinas were fixed in 4% paraformaldehyde in phosphate buffer for 10, 30, or 60 minutes. Radially cut cryosections or fixed HEK cells were immunostained as described previously (Dhingra et al., 2008). MAR sera were diluted 1:100–1:300 in blocking buffer. To determine whether the recognized TRPM1 epitope is intracellular or extracellular, freshly fixed retina was embedded in 4% agarose and sectioned with a Vibratome at 200 μm thickness; sections were incubated in MAR sera or primary antibody for 10 days.
For internalization tests, live retinal slices were incubated in different sera diluted in oxygenated Ames medium for variable durations. Slices were then rinsed, fixed, and incubated in a secondary antibody. In one experiment, a mouse eye was injected intravitreally with 1.5 μl of MAR2 mixed with fluorescein conjugated peanut agglutinin (1.5 μg), which marked the injection site. Retina was fixed and viewed 24 hours later. For HEK cells, transfection was performed using Lipofectamine reagent (Invitrogen). Sections were photographed with an Olympus FV-1000 confocal microscope. Description of immuno-staining results is based on at least 3 independent staining experiments. Cell count on double labeled slices was performed manually on z-stacks using Fluoview.
Western blottings
Protein from frozen retina or HEK cells was prepared as described (Dhingra et al., 2008). After electrophoresis and protein transfer, the membranes were incubated in MAR serum (diluted 1:2000) or anti-TRPM1 antibody (diluted 1:7500) overnight at 4° C followed by secondary antibody for 3 hours at RT.
Certain MAR sera label retinal rod and ON cone bipolar cells
We tested sera obtained from three well-characterized MAR patients who had a normal ERG a-wave but reduced b-wave. To identify the immunoreactive retinal cells, sera were first applied to monkey retinas. Both MAR1 and MAR2 sera, but not MAR3 serum, yielded distinct staining of bipolar cells somas and dendrites (Fig. 1A). Applying control serum gave no staining (Fig. 1B). To determine if only rod bipolar cells or all ON cone bipolar cells were stained, we co-stained for the G-protein subunit Gαo (a marker for ON bipolar cells: Vardi, 1998; Dhingra et al., 2002), and found that practically all cell bodies labeled by Gαo were also stained for MAR2 serum (149/151; 2 experiments) (Fig. 1C–E). Eight cells that stained for MAR2 were unlabeled for Gαo, likely because somatic staining for Gαo is often weak (Vardi, 1998). Thus, both rod bipolar and ON cone bipolar cells are targeted by MAR2. Although bipolar cell staining was robust, the relative intensity of the stain varied, e.g., the staining of bipolar dendrites in the mouse appeared more intense with MAR1 serum compared to MAR2, while MAR2 gave stronger staining in monkey. The intensity of additional stained structures that do not belong to bipolar cells also varied, e.g., in mouse, MAR1, but not MAR2, showed some staining in ganglion cells and axon fibers, and in monkey (but not in mouse) MAR2 stained cone outer segments and both sera stained cone terminals.
Fig. 1
Fig. 1
MAR sera target retinal rod and ON cone bipolar cells (monkey)
A similar pattern of bipolar cell staining was also obtained in baboon and rat. The autoantibodies in MAR1 serum are of the IgG type, because purified IgG gave similar labeling (not shown). To confirm purity of the fraction, we applied anti-IgM secondary antibodies, and this did not reveal any staining.
Autoantibodies in MAR1 and MAR2 sera target TRPM1
To determine whether MAR sera recognize TRPM1, we transfected HEK cells with human TRPM1 fused to myc. Immunostaining these cells with the sera showed that both MAR1 and MAR2 sera stained the TRPM1 transfected cells and, as with anti-TRPM1, the staining was not restricted to the membrane, but was present also in the cytosol (Fig. 2A, B). We verified that each stained cell expressed TRPM1 by co-staining for myc: colocalization was approximately 100% (Fig. 2C, D). MAR sera did not stain untransfected HEK cells, nor did the control serum stain TRPM-1-transfected cells (Fig. 2E, F), To ensure that the MAR sera did not recognize the myc tag, we transfected HEK cells with an unrelated protein (neuropilin1) fused to myc; the anti-myc antibody stained transfected cells but the MAR sera did not (Fig. 2G–H).
Fig. 2
Fig. 2
Autoantibodies in MAR1 and MAR2 sera recognize TRPM1 in cell culture
Next we tested whether MAR sera recognize TRPM1 by Western blotting. Applying the MAR sera to TRPM1-transfected HEK cell protein gave a band at the predicted size (180 kDa) of TRPM1 (Xu et al., 2001; Koike et al., 2010), and this was lacking from untransfected HEK cells (Fig. 2I, middle and left lanes, arrow). The control serum did not show this band in TRPM1-transfected HEK cells (Fig. 2I, right lane). When mouse and monkey retinas were probed with the MAR sera, several bands appeared, but none was at 180 kDa. We confirmed that the mobility of TRPM1 in monkey retina is 180 kDa by probing the Western blots of transfected HEK cells and monkey retina with anti-TRPM1 (Fig. 2J). We conclude that the MAR sera do not easily recognize the denatured endogenous TRPM1.
The experiments presented so far establish that the sera of MAR1 and MAR2 recognize TRPM1, but do not prove that the staining of bipolar cells by the MAR serum represents recognition of TRPM1. Theoretically, the TRPM1 in these cells may go unrecognized, and the observed staining in bipolar cells may be due to an additional autoantibody in the serum. We addressed this issue in the mouse. First, we verified that MAR sera but not a control serum stain bipolar cells (not shown). Then we identified the type of bipolar cells by applying the MAR sera to retinal sections obtained from Grm6-GFP transgenic mice, which express GFP in all and only ON bipolar cells (Fig. 3A–C). We noted almost complete overlap of MAR sera and GFP staining (184 cells out of 195 GFP positive cells showed MAR1 staining and 7 cells stained only for MAR1, 3 experiments; 52 out of 65 GFP-positive cells stained for MAR2, 1 cell stained only for MAR2, 2 experiments). Similar results were obtained by double staining for Gαo (not shown). This indicates that MAR staining in the INL is mostly restricted to ON bipolar cells.
Fig. 3
Fig. 3
In mouse ON bipolar cells, autoantibodies in MAR sera target only TRPM1
Next, we applied the MAR sera to retinal sections obtained from Trpm1−/− mice (3 different animals). In the Trpm1−/− retina, neither MAR1 nor MAR2 serum stained ON bipolar cells (Fig. 3D–I). This suggests that, in bipolar cells, only TRPM1 is recognized.
The TRPM1 epitopes for the autoantibodies are likely to be in the intracellular domain
To determine whether the antibody recognizes an intracellular or extracellular domain, we incubated TRPM1-transfected HEK cells in the MAR sera with or without Triton X-100. In the absence of Triton X-100, only a weak background staining was seen (Fig 4A, B). This lack of staining may indicate that the TRPM1 epitope is intracellular, but it may also indicate a failure of the expressed TRPM1 to integrate into the transfected HEK cell surface. We have thus examined this question in retina, where TRPM1 must be localized to the cell surface to mediate the light response. Staining for MAR1 in the presence of Triton X-100 was strong in both somas and fine dendrites; however the antibody penetrated only down to a depth of about 9 μm. Omitting Triton X-100 retained somatic staining down to a depth of 5–6 μm (because these were cut open by sectioning), but it totally abolished dendritic staining (Fig. 4C–D). Staining for MAR2 in the absence of Triton X-100 gave high background, but no specific staining. In contrast, staining for GABAA receptor (raised against an extracellular epitope: Vardi and Sterling, 1994), remains strong in dendritic tips of cone bipolar cells (and in the inner plexiform layer) even in the absence of Triton X-100 (Fig. 4E–F). These experiments indicate that MAR antibodies recognize intracellular epitopes on the TRPM1 channel, but do not exclude the possibility that a small fraction of the antibody clones are against extracellular epitopes, which are too few to give above-background staining.
Fig. 4
Fig. 4
The epitope recognized by the MAR sera is intracellular and MAR serum is internalized
We have further tested whether the antibodies can be internalized into retinal cells. Incubation of live retinal slices in MAR2 revealed that many horizontal and amacrine cells internalized the antibodies within 1 hour while photoreceptors and bipolar cells required a longer period (Fig. 4G–I). The obtained staining is not due to stickiness of the secondary antibody because incubation in normal horse or goat sera or just in Ames medium followed by anti-human secondary did not result in any staining. However, these sera, as well as normal human serum, were also internalized, as revealed by using the appropriate secondary antibodies. Injecting MAR2 intravitreally and observing the retina 24 hours later also showed internalization, albeit in a smaller fraction of cells.
It has been known for about 20 years that some patients with MAR develop autoantibodies against proteins specific to retinal rod bipolar cells (Milam et al., 1993; Weinstein et al., 1994; Kellner et al., 1995; Adamus, 2009; Lu et al., 2009). Efforts to identify the antigen in bipolar cells have, until now, been unsuccessful. Here we show that certain MAR sera target TRPM1, the non-selective cation channel that is required for light responses in all types of ON bipolar cell (Morgans et al., 2009; Koike et al., 2010). This conclusion is supported by: immunostaining of TRPM1-transfected HEK cells with MAR sera, immunostaining of all types of ON bipolar cells in monkey and wild type mouse retina, and absence of this immunostaining in Trpm1−/− retina.
Different subtypes of MAR disease
The MAR condition was originally diagnosed based on the visual experience of night blindness, photopsias, and a selective reduction of the ERG b-wave. However, clinical diagnosis does not always include ERG recordings, and consequently, certain diagnosed cases may not be restricted to a bipolar cell dysfunction. Indeed several studies identified photoreceptor proteins as the MAR serum targets (Potter et al., 2002; Hartmann et al., 2005; Lu et al., 2009). ERG recordings could potentially differentiate between cases in which the primary target is a photoreceptor or a bipolar cell protein. If photoreceptors are targeted, ERG recordings are expected to show proportionally diminished a- and b-waves [as in Lu et al (1990) for MAR patients]. If bipolar cell proteins are the primary targets, ERG recordings are expected to show a `negative' configuration with selective b-wave reductions but near normal a-waves (Alexander et al., 1992; Keltner et al., 2001; Alexander et al., 2002). The situation is likely to be more complex, as Potter et al. (2002) reported a case of MAR in which ERG was negative but the patient's serum contained antibodies against transducin and did not label bipolar cells. In the future, it will be important to discriminate MAR subtypes by their autoantibodies rather than by ERG and vision tests alone. Because TRPM1 is the only bipolar cell protein implicated in MAR so far, we suggest referring to cases where bipolar cells are targeted as MARTRPM1. The value of discriminating MAR subtypes by targeted antigens will further increase when it becomes possible to specifically eliminate disease-causing autoantibodies from patients' blood.
Possible causes of retinopathy in MARTRPM1
It is most likely that circulating antibodies bind the TRPM1 channel on the ON bipolar cells and either directly block the channel or indirectly interfere with the cells's signal transduction, thereby leading to a loss of night vision and a reduced ERG b-wave. Most cases of MAR report an onset of night blindness (nyctalopia); this is probably because night vision is mediated by the rod bipolar cells, which comprise the majority of ON bipolar cells. In addition to nyctalopia, MAR patients exhibit some impairment of daylight vision (Keltner and Thirkill, 1998; Keltner et al., 2001; Alexander et al., 2002; Alexander et al., 2004; Heckenlively and Ferreyra, 2008), reflecting dysfunction in the ON class of cone bipolar cells, which also utilize TRPM1 (Morgans et al., 2009). Any relative preservation of cone-mediated vision in MAR patients would be achieved via unaffected OFF bipolar cells. Mechanistically, the MAR antibodies could interfere with the signaling by binding either extracellular or intracellular epitopes on the TRPM1 channel. Our experiments suggest that the TRPM1 epitope recognized by MAR sera is intracellular, in which case, autoantibodies would have to be internalized before they can impact ON bipolar cell function. Internalization of several antibodies including normal IgGs has been shown previously (Adamus et al., 1997; Adamus et al., 1998; Shiraga and Adamus, 2002) as well as in our study.
Possible causes of MAR-related autoimmunity
In many cases of MAR, the autoantibodies target photoreceptor proteins (Bazhin et al., 2007). It has been found that healthy melanocytes transcribe many photoreceptor mRNAs, and when these cells become malignant they start to express these proteins. Because the retina is immune-privileged, the body does not recognize these proteins as self and produces autoantibodies, possibly to fight the cancer cells. This explanation does not fit well with the MARTRPM1 disease type because TRPM1 is expressed in normal melanocytes, and in fact is down-regulated in melanoma (Duncan et al., 2001). If, however, downregulation of TRPM1 is a bodily defense mechanism directed against metastatic melanocytes in aggressive melanoma, the generation of anti-TRPM1 antibodies can contribute to this defense.
Acknowledgment
We thank Narender K. Dhingra for help with injection of peanut agglutinin. Supported by the NIH EY11105 (NV), NIH EY08301 (KA); NIH NEI P30 EY01583 (University of Pennsylvania); Illinois Society for the Prevention of Blindness (DJR); Foundation Fighting Blindness (GAF; NSP); Department of Veterans Affairs (NSP); Research to Prevent Blindness (NSP).
  • Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev. 2009;8:410–414. [PMC free article] [PubMed]
  • Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1997;38:283–291. [PubMed]
  • Adamus G, Machnicki M, Elerding H, Sugden B, Blocker YS, Fox DA. Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo. J Autoimmun. 1998;11:523–533. [PubMed]
  • Alexander KR, Barnes CS, Fishman GA, Milam AH. Nature of the cone ON-pathway dysfunction in melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 2002;43:1189–1197. [PubMed]
  • Alexander KR, Fishman GA, Peachey NS, Marchese AL, Tso MO. `On' response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci. 1992;33:477–483. [PubMed]
  • Alexander KR, Barnes CS, Fishman GA, Pokorny J, Smith VC. Contrast-processing deficits in melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 2004;45:305–310. [PubMed]
  • Audo I, et al. TRPM1 is mutated in patients with autosomal-recessive complete congenital stationary night blindness. Am J Hum Genet. 2009;85:720–729. [PubMed]
  • Bazhin AV, Schadendorf D, Willner N, De Smet C, Heinzelmann A, Tikhomirova NK, Umansky V, Philippov PP, Eichmuller SB. Photoreceptor proteins as cancer-retina antigens. Int J Cancer. 2007;120:1268–1276. [PubMed]
  • Bellone RR, Brooks SA, Sandmeyer L, Murphy BA, Forsyth G, Archer S, Bailey E, Grahn B. Differential gene expression of TRPM1, the potential cause of congenital stationary night blindness and coat spotting patterns (LP) in the Appaloosa horse (Equus caballus) Genetics. 2008;179:1861–1870. [PubMed]
  • Bellone RR, Forsyth G, Leeb T, Archer S, Sigurdsson S, Imsland F, Mauceli E, Engensteiner M, Bailey E, Sandmeyer L, Grahn B, Lindblad-Toh K, Wade CM. Fine-mapping and mutation analysis of TRPM1: a candidate gene for leopard complex (LP) spotting and congenital stationary night blindness in horses. Brief Funct Genomics. 2010;9:193–207. [PubMed]
  • Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol. 1988;106:307–311. [PubMed]
  • Dhingra A, Sulaiman P, Xu Y, Fina ME, Veh RW, Vardi N. Probing neurochemical structure and function of retinal ON bipolar cells with a transgenic mouse. J Comp Neurol. 2008;510:484–496. [PMC free article] [PubMed]
  • Dhingra A, Jiang M, Wang TL, Lyubarsky A, Savchenko A, Bar-Yehuda T, Sterling P, Birnbaumer L, Vardi N. Light response of retinal ON bipolar cells requires a specific splice variant of Gào. Journal of Neuroscience. 2002;22:4878–4884. [PubMed]
  • Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, McCarthy JJ. Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol. 2001;19:568–576. [PubMed]
  • Hammock L, Cohen C, Carlson G, Murray D, Ross JS, Sheehan C, Nazir TM, Carlson JA. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma. J Cutan Pathol. 2006;33:599–607. [PubMed]
  • Hartmann TB, Bazhin AV, Schadendorf D, Eichmuller SB. SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int J Cancer. 2005;114:88–93. [PubMed]
  • Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008;30:127–134. [PubMed]
  • Kellner U, Bornfeld N, Foerster MH. Severe course of cutaneous melanoma associated paraneoplastic retinopathy. Br J Ophthalmol. 1995;79:746–752. [PMC free article] [PubMed]
  • Keltner JL, Thirkill CE. Cancer-associated retinopathy vs recoverin-associated retinopathy. Am J Ophthalmol. 1998;126:296–302. [PubMed]
  • Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001;21:173–187. [PubMed]
  • Koike C, Obara T, Uriu Y, Numata T, Sanuki R, Miyata K, Koyasu T, Ueno S, Funabiki K, Tani A, Ueda H, Kondo M, Mori Y, Tachibana M, Furukawa T. TRPM1 is a component of the retinal ON bipolar cell transduction channel in the mGluR6 cascade. Proc Natl Acad Sci U S A. 2010;107:332–337. [PubMed]
  • Lei B, Bush RA, Milam AH, Sieving PA. Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo. Invest Ophthalmol Vis Sci. 2000;41:262–266. [PubMed]
  • Li Z, Sergouniotis PI, Michaelides M, Mackay DS, Wright GA, Devery S, Moore AT, Holder GE, Robson AG, Webster AR. Recessive mutations of the gene TRPM1 abrogate ON bipolar cell function and cause complete congenital stationary night blindness in humans. Am J Hum Genet. 2009;85:711–719. [PubMed]
  • Lu Y, Jia L, He S, Hurley MC, Leys MJ, Jayasundera T, Heckenlively JR. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol. 2009;127:1572–1580. [PubMed]
  • McCall MA, Gregg RG. Comparisons of structural and functional abnormalities in mouse b-wave mutants. J Physiol. 2008;586:4385–4392. [PubMed]
  • Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34:91–100. [PubMed]
  • Morgans CW, Brown RL, Duvoisin RM. TRPM1: the endpoint of the mGluR6 signal transduction cascade in retinal ON-bipolar cells. Bioessays. 2010;32:609–614. [PubMed]
  • Morgans CW, Zhang J, Jeffrey BG, Nelson SM, Burke NS, Duvoisin RM, Brown RL. TRPM1 is required for the depolarizing light response in retinal ON-bipolar cells. Proc Natl Acad Sci U S A. 2009;106:19174–19178. [PubMed]
  • Potter MJ, Adamus G, Szabo SM, Lee R, Mohaseb K, Behn D. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol. 2002;134:128–130. [PubMed]
  • Shen Y, Heimel JA, Kamermans M, Peachey NS, Gregg RG, Nawy S. A transient receptor potential-like channel mediates synaptic transmission in rod bipolar cells. J Neurosci. 2009;29:6088–6093. [PMC free article] [PubMed]
  • Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol. 2002;132:72–82. [PubMed]
  • van Genderen MM, Bijveld MM, Claassen YB, Florijn RJ, Pearring JN, Meire FM, McCall MA, Riemslag FC, Gregg RG, Bergen AA, Kamermans M. Mutations in TRPM1 are a common cause of complete congenital stationary night blindness. Am J Hum Genet. 2009;85:730–736. [PubMed]
  • Vardi N. Alpha subunit of Go localizes in the dendritic tips of ON bipolar cells. Journal of Comparative Neurology. 1998;395:43–52. [PubMed]
  • Vardi N, Sterling P. Subcellular localization of GABA A receptor on bipolar cells in macaque and human retina. Vision Research. 1994;34:1235–1246. [PubMed]
  • Weinstein JM, Kelman SE, Bresnick GH, Kornguth SE. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology. 1994;101:1236–1243. [PubMed]
  • Xu XZ, Moebius F, Gill DL, Montell C. Regulation of melastatin, a TRP-related protein, through interaction with a cytoplasmic isoform. Proc Natl Acad Sci U S A. 2001;98:10692–10697. [PubMed]